IPSC
Century Therapeutics, Inc.NASDAQHealthcare$2.13+2.82%ClosedMarket Cap: $184.4M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.19
P/S
1.74
EV/EBITDA
-88.34
DCF Value
$2.25
FCF Yield
-55.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
90.9%
Operating Margin
-13.8%
Net Margin
-8.8%
ROE
-4.9%
ROA
-4.3%
ROIC
-7.2%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-25.8M | $-19.2M | $-0.22 | — |
| FY 2025 | $109.2M | 88.0% | $-15.0M | $-9.6M | $-0.11 | — |
| Q3 2025 | $0.00 | -Infinity% | $-29.1M | $-34.4M | $-0.40 | — |
| Q2 2025 | $0.00 | -Infinity% | $-34.3M | $-32.5M | $-0.38 | — |
| Q1 2025 | $109.2M | 100.0% | $74.2M | $76.6M | $0.89 | — |
| Q4 2024 | $4.2M | 100.0% | $-37.3M | $-36.1M | $-0.46 | — |
| FY 2024 | $6.6M | 100.0% | $-138.1M | $-126.6M | $-1.61 | — |
| Q3 2024 | $791.0K | 100.0% | $-34.8M | $-31.2M | $-0.37 | — |
| Q2 2024 | $771.0K | 100.0% | $-34.8M | $-31.2M | $-0.38 | — |
| Q1 2024 | $855.0K | 100.0% | $-31.3M | $-28.1M | $-0.45 | — |
| Q4 2023 | $268.0K | -8219.4% | $-43.8M | $-39.4M | $-0.66 | — |
| FY 2023 | $2.2M | 100.0% | $-146.5M | $-136.7M | $-2.30 | — |